Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

memo - Magazine of European Medical Oncology

Issue 2/2011

Content (20 Articles)

Editorial

Gastrointestinal cancers – still many questions to be resolved

E. Wöll

Editorial

ASH 2010: new drugs and novel therapeutic concepts on the move

M. Steurer

CECOG News

CECOG/BC1.2.001 – International Clinical Trials Workshop, July 1–2, Cluj-Napoca

Dagmar Just

Review

Current treatment strategies of oesophageal carcinoma

T. Ruhstaller, M. Stahl

Review

Gastric cancer – still many questions to be solved

F. Lordick, G. Schumacher, M. Becker-Schiebe

Short Review

Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer

O. Coutelle, M. Hallek, U. T. Hacker

Short Review

Bowel First? Simultaneous Resection? Liver First? Treatment options in patients with colorectal cancer and resectable synchronous liver metastases

M. Zitt

Short Review

Can stereotactic radiofrequency ablation replace liver resection?

R. Bale, G. Widmann

Short Review

Adjuvant chemotherapy in colon carcinoma stages II and III

G. Resch, J. Thaler

Short Review

(Neo-)Adjuvant radiochemotherapy in stage II/III rectal cancer

W. Hoffmann, F. Lordick, M. Becker-Schiebe

Short Review

Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas

D. Koeberle, P. Samaras

Short Review

Side effect management during treatment of gastrointestinal (GI) cancers

M. Becker-Schiebe, F. Lordick, W. Hoffmann

Short Review

Contribution of PET-CT in the management of gastrointestinal cancer

M. Gabriel

ASH Report

Novel Developments in AML – ASH 2010

W. R. Sperr, P. Valent

ASH Report

Myelodysplastic Syndromes (MDS) – News from ASH 2010

T. Nösslinger, M. Pfeilstöcker

ASH Report

Indolent lymphomas and mantle cell lymphoma: New developments as of ASH 2010

J. Drach

ASH Report

Multiple myeloma at ASH 2010: Some points that might change our daily practice

E. Gunsilius, W. Willenbacher

ASH Report

ASH update 2010: Chronic lymphocytic leukaemia

M. Steurer, S. Schmidt

ASH Report

Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010

T. Melchardt, S. W. Hofbauer, R. Greil, G. Hopfinger

ASH Report

What's new in CML? Highlights of ASH 2010

J. Rudzki, D. Wolf

May 11
Issue: Special Issue 1/2011
Jun 11
Issue: Special Issue 2/2011

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits